


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Vosoritide for treating achondroplasia in people 4 months and over ID6488


Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
BioMarin Pharmaceuticals (vosoritide)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	 Allied Health Professionals Federation
Arthritis and Musculoskeletal Alliance	Board of Community Health Councils in
Child Growth Foundation	Wales
Dwarf Sports Association	 British National Formulary
 Foundation Exploring Skeletal 	 Care Quality Commission
Dysplaisia Together	 Department of Health - Northern Ireland
Gene People	 Healthcare Improvement Scotland
Genetic Alliance UK	 Medicines and Healthcare products
Little People UK	Regulatory Agency
 Restricted Growth Association UK 	 National Association of Primary Care
 South Asian Health Foundation 	 National Pharmacy Association
Specialised Healthcare Alliance	 NHS Confederation
	Scottish Medicines Consortium
Healthcare professional groups	Welsh Government
 Association of Genetic Nurses & 	 NHS Wales Joint Commissioning
Counsellors	Committee
British Association of Paediatric	
Surgeons	Possible comparator companies
British Geriatrics Society	Ascendis Pharma (Ionapegsomatropin)
British Institute of Musculoskeletal	Ferring (somatropin)
Medicine	Merck Serono (somatropin)
British Myology Society	Novo Nordisk (somatropin,
British Orthopaedic Association	somapacitan)
British Paediatric and Adolescent	Pfizer (somatropin, somatrogon)
Bone Group	Sandoz (somatropin)
British Pain Society British Consists for Oblibbands	Delevert recent was
British Society for Children's Orthoppedia Surgery	Relevant research groups
Orthopaedic Surgery	Bone Research Society Chronic Boin Bolisty Condition
British Society for Genetic Medicine British Society for Readistric	Chronic Pain Policy Coalition Cash range Museulaskalatal Croun
British Society for Paediatric Endocripology and Diphetes	Cochrane Musculoskeletal Group
Endocrinology and Diabetes	Genomics England MBC Clinical Trials Unit
British Society for RheumatologyBritish Society of Physical and	MRC Clinical Trials Unit Netional Institute for Health Beautyph
British Society of Physical and Rehabilitation Medicine	National Institute for Health Research



Provisional Consultees Provisional Commentators (no right to submit or appeal) Neonatal and Paediatric Pharmacists Orthopaedic Research UK Group Pain Relief Foundation Physiotherapy Pain Association Society of Back Pain Research Royal College of General Practitioners Skeletal Dysplasia Group Royal College of Nursing The Society for Research in Royal College of Paediatrics & Child Rehabilitation Health Wellcome Trust Royal College of Pathologists Royal College of Physicians Associated Public Health groups Public Health Wales Royal College of Surgeons Royal Pharmaceutical Society UK Health Security Agency Royal Society of Medicine Evidence Review Group Society for Endocrinology National Institute for Health Research **UK Clinical Pharmacy Association** Health Technology Assessment Chartered Society of Physiotherapy Programme (NETSCC) Royal College of Occupational **Therapists** Primary Care Rheumatology and Musculoskeletal Medicine Society **Others** Department of Health and Social Care Evelina London Children's Hospital, Guy's and St Thomas' NHS **Foundation Trust** NHS England Department of Children's Orthopaedics, University Hospital Southampton NHS Foundation Trust Department of Endocrinology, University Hospitals Birmingham **Foundation Trust** Department of Orthopaedic and Spine Surgery, Great Ormond Street Hospital for Children NHS Foundation Trust Developmental Disorders Clinic, Manchester Centre for Genomic Medicine. Manchester NHS Foundation Trust Paediatric Trauma and Orthopaedic Surgery, University Hospitals Bristol NHS Foundation Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected



characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.